Cardiomedex’s Partners

PHYSIOGENEX

Physiogenex is a preclinical CRO specialized in metabolic disorders, based in Toulouse, France. They have been developing and applying their expertise in metabolic diseases for more than 15 years in order to provide reliable preclinical studies for the treatment of these pathologies. They develop innovative models for all metabolic diseases and their complications as well as a wide range of tests to demonstrate the effectiveness of drug candidates.

Physiogenex and Cardiomedex work in close collaboration with each other as they share the same CEO and facilities. Together, our two companies can provide a fully integrated approach to cardiometabolic diseases, enabling us to design large-scale studies to evaluate the effect of drug candidates on both cardiac and metabolic functions in predictive and integrative models.

Visit the Physiogenex website for more information.

Team 8 of I2MC (INSERM)

Celine Gales’ team of highly skilled scientists and physicians, is specialized in cardiac structure and pharmacology.

The team’s research focuses on the cardiomyocyte architecture and identification of the molecular determinants of adult cardiomyocyte morphology & cardiac tissue organization. Accordingly, the team has developed expertise in high resolution microscopy (Electron and Atomic Force Microscopy) to explore 3D organization of the cardiomyocyte’s lateral membrane in physio- and patho-physiology. They have therefore been able to provide an accurate characterisation of periodic crests filled with subsarcolemmal mitochondria. More recently, they have pinpointed the specific role of crest disorganization in the set-up of cardiac dysfunction, specifically in heart failure with preserved ejection fraction (HFpEF).

The team also has extensive expertise in cell surface receptor pharmacology with a specific emphasis on cardiac GPCRs (G-Protein-Coupled Receptors) that are explored using the BRET technology. Specifically, Celine’s team has focused on the molecular mechanisms underlying biased efficacy of GPCR ligands, enabling them to provide the first description of natural-biased efficacy of Angiotensin II derivates.

Together with Celine’s team, Cardiomedex is implementing an R&D program to develop and characterize innovative models, mainly focusing on heart failure with preserved ejection fraction.

Visit the Inserm Team website for more information.